Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Macrophage Activation Syndrome

Alexei A. Grom, MD  |  Issue: December 2010  |  

Pathophysiology

The pathological mechanisms of MAS are not fully understood. In clinically similar primary HLH, the uncontrolled proliferation of T cells and macrophages has been linked to decreased natural killer (NK) cell and cytotoxic T cell function, often due to mutations in the gene encoding perforin.8,10 Perforin is a protein that cytolytic cells utilize to induce apoptosis of target cells, such as tumor cells or cells infected by viruses. In a sizable proportion of patients with primary HLH, the disease is caused by mutations in another gene, MUNC13-4.11 The protein encoded by the MUNC13-4 gene is involved in the release of perforin into the immune synapse with a target cell. Although the cytolytic cells of patients with MUNC13-4 mutations produce sufficient amounts of perforin, their ability to kill target cells is greatly diminished. Defects in the granule-dependent cytotoxic functions of lymphocytes have also been implicated in several other genetic diseases associated with the hemophagocytic syndrome.

Recent observations suggest that as in HLH, MAS patients have profoundly depressed NK cell function, often associated with abnormal perforin expression, and these abnormalities are associated with specific MUNC13-4 and perforin gene polymorphisms.12,13 Although the exact pathways that could link cytolytic abnormalities in these patients with excessive expansion of macrophages are not clear, the presence of defects in the granule-dependent cytotoxic activity of lymphocytes in several diseases associated with hemophagocytic syndromes highlights the importance of this function in restoring the immune system to a state of equilibrium during some inflammatory responses.

ADVERTISEMENT
SCROLL TO CONTINUE

Two possible scenarios explaining how cytolytic dysfunction may lead to excessive activation of macrophages have been suggested in the literature. One is related to the fact that HLH/MAS patients appear to have a diminished ability to control some infections.14 More specifically, in this scenario, NK cells and cytotoxic T lymphocytes (CTLs) fail to kill infected cells and thus remove the source of antigenic stimulation. Such persistent antigen stimulation leads, in turn, to persistent antigen-driven activation and proliferation of T cells associated with persistent production of cytokines that stimulate macrophages. A second scenario is based on the observations that, in some circumstances, cytotoxic cells may be directly involved in induction of apoptosis of activated macrophages and T cells during the contraction stage of the immune response.15 In both scenarios, cytotoxic dysfunction leads to persistent expansion of T cells and macrophages and escalating production of proinflammatory cytokines. Indeed, the clinical findings during the acute phase of MAS can largely be explained as a consequence of the prolonged production of cytokines and chemokines.

Related Articles
    Fellows' Forum Case Report: Hemophagocytic Lymphohistiocytosis

    Fellows’ Forum Case Report: Hemophagocytic Lymphohistiocytosis

    The patient was a 48-year-old woman who saw her primary care physician for a flu-like illness three months prior to admission. Her symptoms initially improved, but recurred one month later; she was treated symptomatically, and again symptoms resolved. Two months later, she presented to an outside facility’s emergency department with fever to 103ºF, with associated…

    Diagnosing & Treating Hemophagocytic Lymphohistiocytosis in Adults

    Primary hemophagocytic lymphohistiocytosis (HLH) is caused by genetic mutations and inherited syndromes; it therefore occurs in the pediatric age group. Secondary HLH, however, is more common in adults and is often triggered by other disease states, such as malignancies, chronic immuno­suppression, infections and autoimmune disease.1,2 Macrophage activation syndrome (MAS) is a subset of secondary HLH…